Skip to main content
Journal cover image

Trithiol ligand provides tumor-targeting 191Pt-complexes with high molar activity and promising in vivo properties.

Journal articles  - Journal Article
Obata, H; Tsuji, AB; Feng, Y; Zheng, Y; Sudo, H; Sugyo, A; Tornow, W; Finch, SW; Minegishi, K; Suzuki, H; Ichinose, J; Ogawa, M; Zhang, M-R ...
Published in: Nucl Med Biol
2025

PURPOSE: The Auger electron-emitting radionuclide 191Pt is a promising candidate for radiopharmaceutical therapy. Herein, we explored novel labeling methods for 191Pt using thiol-containing ligands to improve the in vivo stability and targeting ability of 191Pt-labeled complexes. METHODS: We synthesized dithiol-containing N2S2 and NS2 ligands, and a trithiol ligand, and then compared their radiochemical reactivity with 191Pt. [191Pt]Pt-trithiol was synthesized and its biodistribution was evaluated in mice and compared with free 191Pt. Finally, a 191Pt-trithiol complex targeting prostate-specific membrane antigen (PSMA): [191Pt]Pt-trithiol-PSMA was developed and evaluated in mice bearing tumor xenografts and compared with a 191Pt-complex labeled via monothiol-containing Cys ([191Pt]Pt-Cys-PSMA). RESULTS: A comparison of N2S2, NS2, and trithiol showed that the trithiol ligand is the best for producing 191Pt-labeled compounds in high yield and as a single peak in preparative HPLC. Notably, the trithiol ligand made 191Pt-labeled compounds and precursors separatable, achieving 191Pt-labeled products with a high molar activity: 200-400 mCi/μmol (7.4-14.8 GBq/μmol) at EOS. Additionally, [191Pt]Pt-trithiol and [191Pt]Pt-trithiol-PSMA were stable in vivo with rapid clearance compared with free 191Pt and [191Pt]Pt-Cys-PSMA. [191Pt]Pt-trithiol-PSMA resulted in a low uptake in most normal organs and a high uptake in the kidneys and prostate cancer with PSMA expression. CONCLUSIONS: This study demonstrated that a labeling method with trithiol for Pt radionuclides achieves 191Pt-labeled products with high molar activity. 191Pt-trithiol-PSMA showed promising in vivo stability and tumor-targeting specificity, which should facilitate the pharmaceutical development of Pt radionuclides for radiopharmaceutical therapy, especially Auger electron cancer therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nucl Med Biol

DOI

EISSN

1872-9614

Publication Date

2025

Volume

146-147

Start / End Page

109043

Location

United States

Related Subject Headings

  • Tissue Distribution
  • Sulfhydryl Compounds
  • Radiochemistry
  • Nuclear Medicine & Medical Imaging
  • Mice
  • Male
  • Ligands
  • Humans
  • Glutamate Carboxypeptidase II
  • Cell Line, Tumor
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Obata, H., Tsuji, A. B., Feng, Y., Zheng, Y., Sudo, H., Sugyo, A., … Zalutsky, M. R. (2025). Trithiol ligand provides tumor-targeting 191Pt-complexes with high molar activity and promising in vivo properties. Nucl Med Biol, 146–147, 109043. https://doi.org/10.1016/j.nucmedbio.2025.109043
Obata, Honoka, Atsushi B. Tsuji, Yutian Feng, Yongxiang Zheng, Hitomi Sudo, Aya Sugyo, Werner Tornow, et al. “Trithiol ligand provides tumor-targeting 191Pt-complexes with high molar activity and promising in vivo properties.” Nucl Med Biol 146–147 (2025): 109043. https://doi.org/10.1016/j.nucmedbio.2025.109043.
Obata H, Tsuji AB, Feng Y, Zheng Y, Sudo H, Sugyo A, et al. Trithiol ligand provides tumor-targeting 191Pt-complexes with high molar activity and promising in vivo properties. Nucl Med Biol. 2025;146–147:109043.
Obata, Honoka, et al. “Trithiol ligand provides tumor-targeting 191Pt-complexes with high molar activity and promising in vivo properties.” Nucl Med Biol, vol. 146–147, 2025, p. 109043. Pubmed, doi:10.1016/j.nucmedbio.2025.109043.
Obata H, Tsuji AB, Feng Y, Zheng Y, Sudo H, Sugyo A, Tornow W, Finch SW, Minegishi K, Suzuki H, Ichinose J, Ogawa M, Zhang M-R, Zalutsky MR. Trithiol ligand provides tumor-targeting 191Pt-complexes with high molar activity and promising in vivo properties. Nucl Med Biol. 2025;146–147:109043.
Journal cover image

Published In

Nucl Med Biol

DOI

EISSN

1872-9614

Publication Date

2025

Volume

146-147

Start / End Page

109043

Location

United States

Related Subject Headings

  • Tissue Distribution
  • Sulfhydryl Compounds
  • Radiochemistry
  • Nuclear Medicine & Medical Imaging
  • Mice
  • Male
  • Ligands
  • Humans
  • Glutamate Carboxypeptidase II
  • Cell Line, Tumor